Download PDF
Geburtshilfe Frauenheilkd 2004; 64(4): R53-R76
DOI: 10.1055/s-2004-820932
GebFra-Refresher

Georg Thieme Verlag KG Stuttgart · New York

Ovarielles Überstimulationssyndrom-update - Teil 1

H. Binder1 , S. Cupisti1 , R. Dittrich1 , F. Einhaus2 , J. Krieg1 , A. Müller1 , R. Strauß3 , M. W. Beckmann1
  • 1Frauenklinik, Friedrich-Alexander-Universität, Erlangen
  • 2Klinik f. Anästhesiologie, Friedrich-Alexander-Universität, Erlangen
  • 3Medizinische Klinik I, Friedrich-Alexander-Universität, Erlangen
Further Information

Publication History

Publication Date:
03 May 2004 (online)

Also available at
    Permissions and Reprints

Inzidenz und Pathogenese

Literatur

  • 1 Di Carlo C, Bruno P, Cirillo D, Morgera R, Pellicano M, Nappi C. Increased concentrations of renin, aldosterone and Ca125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulation syndrome.  Hum Reprod. 1997;  12 2115-2117
    CrossrefPubMedGoogle Scholar
  • 2 Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart and Costagliola G S. Brief report: ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor.  N Engl J Med. 2003;  349 760-766
    CrossrefPubMedGoogle Scholar
  • 3 Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS).  Hum Reprod Update. 2003;  9 77-96
    CrossrefPubMedGoogle Scholar
  • 4 Deutsches IVF-Register . www.deutsches-ivf-register.de .  Jahrbuch. 2002;  1-32
    PubMedGoogle Scholar
  • 5 Ben-Chetrit A, Eldar-Geva T, Gal M, Huerta M, Mimon T, Algur N, Diamant Y Z, Margalioth E J. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial.  Hum Reprod. 2001;  16 1880-1884
    CrossrefPubMedGoogle Scholar
  • 6 Bellver J, Muñoz E A, Ballesteros A, Soares S R, Bosch E, Simón C, Pellicer A, Remohí J. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study.  Hum Reprod. 2003;  18 2283-2288
    CrossrefPubMedGoogle Scholar
  • 7 Ludwig M, Gembruch U, Bauer O, Diedrich K. Ovarian hyperstimulation syndrome (OHSS) in a spontaneous pregnancy with fetal and placental triploidy: information about the general pathophysiology of OHSS.  Hum Reprod. 1998;  13 2082-2087
    CrossrefPubMedGoogle Scholar
  • 8 Schenker J G. Prevention and treatment of ovarian hyperstimulation.  Hum Reprod. 1993;  8 653-659
    PubMedGoogle Scholar
  • 9 Schneider K TM. Wissenschaftlich begründete Geburtshilfe.  Gynäkologe. 2003;  35 840-844
    PubMedGoogle Scholar
  • 10 Kol S. Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent!.  Hum Reprod. 2003;  18 1557-1558
    CrossrefPubMedGoogle Scholar
  • 11 Kissler S, Siebzehnrübl E, Kaufmann M. Von der Pathophysiologie und Prävention des ovariellen Überstimulationssyndroms (OHSS) bis zur stadiengerechten Therapie.  Geburtsh Frauenheilk. 2002;  62 1155-1161
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Schubert J, Merz M, Distler W. Das ovarielle Überstimulationssyndrom.  Gynäkologe. 2002;  35 363-371
    CrossrefPubMedGoogle Scholar
  • 13 Keck C, Neulen J, Behre H M, Breckwoldt M. Endokrinologie, Reproduktionsmedizin, Andrologie. 2. Aufl. Stuttgart; Thieme Verlag 2002
    Google Scholar
  • 14 Geisthövel F, Christ L, Haibt L, Ochsner A. Assisted reproductive techniques: risks, contraindications, prognostic factors, therapeutic strategies.  Andrologia. 2003;  35 168-169
    CrossrefPubMedGoogle Scholar
  • 15 Forman R G. Severe OHSS - an unacceptable price.  Hum Reprod. 1999;  14 2687-2688
    CrossrefPubMedGoogle Scholar
  • 16 Golan A, Ron-el R, Herman R, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome an update review.  Obst Gynecol Surv. 1989;  44 430-440
    PubMedGoogle Scholar
  • 17 Kaiser U B. The pathogenesis of the ovarian hyperstimulation syndrome.  N Engl J Med. 2003;  349 729-732
    CrossrefPubMedGoogle Scholar
  • 18 Vasseur C, Rodien P, Beau I, Desroches A, Gérard C, de Poncheville L, Chaplot S, Savagner F, Croué A, Mathieu E, Lahlou N, Descamps P, Misrahi M. Brief report: a chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome.  N Engl J Med. 2003;  349 753-759
    CrossrefPubMedGoogle Scholar
  • 19 Tozer A J, Al-Shawaf T, Gillott C MY, Lower A M, Grudzinskas J G. Excessive follicular response to controlled ovarian stimulation in a woman with menopausal FSH levels: Case report.  Hum Reprod. 2004;  19 107-109
    CrossrefPubMedGoogle Scholar
  • 20 Delbaere A, Smits G, Olatunbosun O, Pierson R. Vassart G, Costagliola S. New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?.  Hum Reprod. 2004;  DOI: 10.1093/humrep/deh124,1-4
    PubMedGoogle Scholar
  • 21 Lyons C A, Wheeler C A, Frishman G N, Hackett R J, Seifer D B, Haning Jr. RV early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.  Hum Reprod. 1994;  9 792-799
    PubMedGoogle Scholar
  • 22 Neulen J. Das ovarielle Überstimulationssyndrom Reproduktionsmedizin.  . 2001;  17 149-152
    PubMedGoogle Scholar
  • 23 McElhinney B, Ardill J, Caldwell C, Lloyd F, McClure N. Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others?.  Hum Reprod. 2002;  17 1548-1553
    CrossrefPubMedGoogle Scholar
  • 24 Wang T H, Horng S G, Chang C L, Wu H M, Tsai Y J, Wang H S, Soong Y K. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor.  J Clin Endocrinol Metab. 2002;  87 3300-3308
    CrossrefPubMedGoogle Scholar
  • 25 Meldrum D R. Vascular endothelial growth factor, polycystic ovary syndrome, and ovarian hyperstimulation syndrome.  Fertil Steril. 2002;  78 1170-1171
    CrossrefPubMedGoogle Scholar
  • 26 Orvieto R. Prediction of ovarian hyperstimulation syndrome: Challenging the estradiol mythos.  Hum Reprod. 2003;  18 665-667
    CrossrefPubMedGoogle Scholar
  • 27 Ito M, Harada T, Iwabe T, Tanikawa M, Terakawa N. Cytokine levels in a patient with severe ovarian hyperstimulation syndrome before and after the ultrafiltration and reinfusion of ascitic fluid.  J Ass Reprod Gen. 2000;  17 118-120
    PubMedGoogle Scholar
  • 28 Abramov Y, Schenker J G, Lewin A, Kafka I, Jaffe H, Barak V. Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndome.  Fertil Steril. 2001;  76 51-57
    CrossrefPubMedGoogle Scholar
  • 29 Levinsohn-Tavor O, Friedler S, Schachter M, Raziel A, Strassburger D, Ron-El R. Coasting - what is the best formula?.  Hum Reprod. 2003;  18 937-940
    CrossrefPubMedGoogle Scholar
  • 30 Ludwig M, Bauer O, Lopens A, Jelkmann W, Diedrich K. Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome.  Hum Reprod. 1998;  13 30-32
    CrossrefPubMedGoogle Scholar
  • 31 Artini P G, Monti M, Fasciani A, Battaglia C, D'Ambrogio G, Genazzani A R. Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome.  Eur J Obstet Gynecol Reprod Biol. 2002;  101 169-174
    CrossrefPubMedGoogle Scholar
  • 32 Mathur R, Hayman G, Bansal A, Jenkins J. Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception.  Fertil Steril. 2002;  78 1154-1158
    CrossrefPubMedGoogle Scholar
  • 33 Hammadeh M E, Fischer-Hammadeh C, Hofmeister H, Huebner U, Georg T, Rosenbaum P, Schmidt W. Fibroblast growth factor (FGF), intracellular adhesion molecule (sICAM-1) level in serum and follicular fluid of infertile women with polycystic ovarian syndrome, endometriosis and tubal damage, and their efect on ICSI outcome.  AJRI. 2003;  50 124-130
    PubMedGoogle Scholar
  • 34 Gokmen O, Ugur M, Ekin M, Keles G, Turan C, Oral H. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study.  Eur J Obstet Gynecol Reprod Biol. 2001;  96 187-192
    CrossrefPubMedGoogle Scholar
  • 35 Jäger W, Diedrich K, Wild L. Elevated levels of CA 125 in serum of patients suffering from ovarian overstimulation syndrome.  Fertil Steril. 1987;  48 675-678
    PubMedGoogle Scholar
  • 36 Delvigne A, Kostyla K, De Leener A, Lejeune B, Cantiniaux B, Bergmann P, Rozenberg S. Metabolic characteristics of women who developed ovarian hyperstimulation syndrome.  Hum Reprod. 2002;  17 1994-1996
    CrossrefPubMedGoogle Scholar
  • 37 Aboulghar M. Prediction of ovarian hyperstimulation syndrome (OHSS): Estradiol level has an important role in the prediction of OHSS.  Hum Reprod. 2003;  18 1140-1141
    CrossrefPubMedGoogle Scholar
  • 38 Thomas K, Searle T, Quinn A, Wood S, Lewis-Jones I, Kingsland C. The value of routine estradiol monitoring in assisted conception cycles.  Acta Obstetricia et Gynecologica Scandinavica. 2002;  81 551-554
    CrossrefPubMedGoogle Scholar
  • 39 Foong L C, Bhagavath B, Kumar J, Ng S C. Ovarian hyperstimulation syndrome is associated with reversible impairment of vascular reactivity.  Fertil Steril. 2002;  78 1159-1163
    CrossrefPubMedGoogle Scholar
  • 40 Enskog A, Henriksson M, Unander M, Nilsson L, Brännström M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization.  Fertil Steril. 1999;  71 808-814
    CrossrefPubMedGoogle Scholar
  • 41 Ho H Y, Lee R KK, Lin M H, Hwu Y M. Estradiol level on day 9 as a predictor of risk for ovarian hyperresponse during controlled ovarian hyperstimulation.  J Ass Reprod Gen. 2003;  20 222-226
    PubMedGoogle Scholar
  • 42 Orvieto R, Leites T, Abir R, Bar J, Yoeli R, Feldberg D, Fisch B. Interleukin-2 production in whole blood cell cultures of women undergoing controlled ovarian hyperstimulation for assisted reproduction technology cycles.  AJRI. 2003;  50 220-223
    PubMedGoogle Scholar
  • 43 Nakamura Y, Takasaki A, Sugino N, Tamura H, Takiguchi S, Takayama H, Harada A, Kato H. Studies on the effects of initial injection doses of follicle stimulating hormone on the pregnancy and the ovarian hyperstimulation syndrome incidence in polycystic ovarian syndrome patients.  Reprod Med Biol. 2003;  2 63-67
    CrossrefPubMedGoogle Scholar
  • 44 Ando H, Furugori K, Shibata D, Harata T, Murata Y, Mizutani S. Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series.  Hum Reprod. 2003;  18 1219-1222
    CrossrefPubMedGoogle Scholar
  • 45 Ujioka T, Matsuura K, Tanaka N, Okamura H. Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model.  Hum Reprod. 1998;  13 3009-3015
    CrossrefPubMedGoogle Scholar
  • 46 Ludwig M, Diedrich K. Evaluation of an optimal luteal phase support protocol in IVF.  Acta Obstet Gynecol Scand. 2001;  80 452-466
    CrossrefPubMedGoogle Scholar
  • 47 Ludwig M, Doody K J, Doody K M. Use of recombinant human chorionic gonadotropin in ovulation induction.  Fertil Steril. 2003;  79 1051-1059
    CrossrefPubMedGoogle Scholar
  • 48 Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome.  Fertil Steril. 2004;  81 1-5
    PubMedGoogle Scholar
  • 49 McDonough P G. Vascular endothelial growth factor - mediator of OHSS?.  Fertil Steril. 2003;  79 1466-1467
    PubMedGoogle Scholar
  • 50 Endo T, Honnma H, Hayashi T, Chida M, Yamazaki K, Kitajima Y, Azumaguchi A, Kamiya H, Kudo R. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos.  Hum Reprod. 2002;  17 2548-2551
    CrossrefPubMedGoogle Scholar
  • 51 Lainas T, Petsas G, Stavropoulou G, Alexopoulou E, Iliadis G, Minaretzis D. Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization.  Fertil Steril. 2002;  78 529-533
    CrossrefPubMedGoogle Scholar
  • 52 Schröder A K, Schöpper B, Al-Hasani S, Diedrich K, Ludwig M. Unilateral follicular aspiration and in-vitro maturation before contralateral oocyte retrieval: a method to prevent ovarian hyperstimulation syndrome.  Eur J Obstet Gynecol Reprod Biol. 2003;  110 186-189
    CrossrefPubMedGoogle Scholar
  • 53 Evbuomvan I O, Davison J M, Baylis P H, Murdoch A P. Altered osmotic threshold for arginine vasopressin secretion and thirst during superovulation and in ovarian hyperstimulation syndrome (OHSS): relevance to pathophysiology of OHSS.  Fertil Steril. 2001;  75 933-941
    CrossrefPubMedGoogle Scholar
  • 54 Parsanezhad M E, Alborzi S, Pakniat M, Schmidt E H. A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome.  Fertil Steril. 2003;  80 1151-1155
    CrossrefPubMedGoogle Scholar
  • 55 Amarin Z O. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome: An aggressive, but perhaps life-saving procedure.  Hum Reprod. 2003;  18 659-664
    CrossrefPubMedGoogle Scholar
  • 56 Bellver J, Escudero E, Pellicer A. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome (OHSS): Ovarian mutilating surgery is not an option in the management of severe OHSS.  Hum Reprod. 2003;  18 1363-1367
    CrossrefPubMedGoogle Scholar
  • 57 Chen C D, Chao K H, Yang J H, Chen S U, Ho H N, Yang Y S. .  Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome Fertil Steril. 2003;  80 86-90
    PubMed
  • 58 Avril C, Bastite L, Chaput-Toupin E, Villière J. Does ectrem obesity have an impact on ovarian response and outcome of infertile women included in IVF program.  Fertil Steril. 2003;  80 (Suppl 3) S178-179
    PubMedGoogle Scholar
  • 59 Yarali H, Yildiz B O, Demirol A, Zeyneloglu H B, Yigit N, Bükülmez O, Koray Z. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial.  Hum Reprod. 2002;  17 289-294
    CrossrefPubMedGoogle Scholar
  • 60 Kahraman S, Yakin K, Vanlioglu F, Donmez E, Karlikaya G, Yakup K. Metformin as an adjuvant therapy in patients with polycystic ovaries undergoing controlled ovarian stimulation.  Hum Reprod. 2003;  18 40 xviii-42 xviii, 115
    PubMedGoogle Scholar
  • 61 Chang A S, Odem R R, Ratts V S. Addition of Metformin with gonadotropin stimulation in PCOS patients.  Fertil Steril. 2003;  80 (Suppl 3) 110-111
    PubMedGoogle Scholar
  • 62 Vanlioglu F, Kahraman S, Karlikaya G, Karagozoglu H, Aygun M. Effect of metformin on subgroups pf patients with polycystic ovaries undergoing controlled ovarian stimulation for assisted reproduction.  Fertil Steril. 2003;  80 (Suppl 3) 111
    PubMedGoogle Scholar
  • 63 Vanky E, Kjørød S B, Maesel A, Bjerve K S, Carlsen S M. Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome.  Fertil Steril. 2004;  81 459-462
    CrossrefPubMedGoogle Scholar
  • 64 Itskovitz-Eldor J, Kol S, Mannaerts B. Use of single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing controlled ovarian stimulation for assisted reproduction, with special refernce to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.  Hum Reprod. 2000;  15 1965-1968
    CrossrefPubMedGoogle Scholar
  • 65 Gomez R, Gonzalez M, Simon C, Remohi J, Pellicer A. Tyroxine hydroxylase (TH) downregulation in hyperstimulated ovaries reveals the dopamine agonist bromocriptine (Br2) as an effective and specific method to block increased vascular permeability (VP) in OHSS.  Fertil Steril. 2003;  80 43-44
    PubMedGoogle Scholar
  • 66 Oelsner G, Cohen S B, Soriano D, Admon D, Mashiach S, Carp H. Minimal surgery for twisted ischaemic adnex can preserve ovarian function.  Hum Reprod. 2003;  18 2599-2602
    CrossrefPubMedGoogle Scholar
  • 67 Abramov Y, Fatum M, Abrahamov D, Schenker J G. Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report.  Fertil Steril. 2001;  75 1228-1230
    CrossrefPubMedGoogle Scholar
  • 68 Kissler S, Neidhardt B, Siebzehnrübl E, Schmitt H, Tschaikowsky K, Wildt L. The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation syndrome: a case report.  Eur J Obstet Gynecol Reprod Biol. 2001;  99 131-134
    CrossrefPubMedGoogle Scholar
  • 69 Abuzeid M I, Nassar Z, Massaad Z, Weiss M, Ashraf M, Fakih M. Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome.  Hum Reprod. 2003;  18 370-373
    CrossrefPubMedGoogle Scholar
  • 70 Al-Ramahi M, Leader A, Claman P, Spence. J First report of a pigtail catheter to drain ascites associated with OHSS.  Hum Reprod. 2003;  18 2235
    CrossrefPubMedGoogle Scholar
  • 71 Abuzeid M I. First report of a pigtail catheter to drain ascites associated with OHSS.  Hum Reprod. 2003;  18 2235-a
    PubMedGoogle Scholar
  • 72 Dulitzky M, Cohen S B, Inbal A, Seidman D S, Sorianio D, Lidor A, Mashiach S, Rabinovici J. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome.  Fertil Steril. 2002;  77 463-467
    CrossrefPubMedGoogle Scholar
  • 73 Stewart J A, Hamilton P J, Murdoch A P. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques.  Hum Reprod. 1997;  12 2167-2173
    CrossrefPubMedGoogle Scholar
  • 74 Arya R, Shehata H A, Patel R K, Sahu S, Rajasingam D, Harrington K F, Nelson-Piercy C, Parsons J H. Internal jugular vein thrombosis after assisted conception therapy.  Br J Haematol. 2001;  115 153-155
    CrossrefPubMedGoogle Scholar
  • 75 Stewart J A, Hamilton P J, Murdoch A P. Upper limb thrombosis associated with assisted conception treatment.  Hum Reprod. 1997;  12 2174-2175
    CrossrefPubMedGoogle Scholar
  • 76 Ulug U, Aksoy E, Erden H, Bayazit N, Bahçeci M. Bilateral internal jugular venous thrombosis following successful assisted conception in the absence of ovarian hyperstimulation syndrome.  Eur J Obstet Gynecol Reprod Biol. 2003;  109 231-233
    CrossrefPubMedGoogle Scholar
  • 77 McGowan B MC, Kay L A, Perry D J. Deep vein thrombosis followed by internal jugular vein thrombosis as a complication of in vitro fertilization an a woman heterozygous for the prothrombin 3′UTR and factor V Leiden mutations.  Am J Hematol. 2003;  73 276-278
    CrossrefPubMedGoogle Scholar
  • 78 Ogawa S, Minakami H, ArakiI S, Ohno T, Motoyama M, Shibahara H, Sato I. Physiology: a rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome.  J Ass Reprod Gen. 2001;  18 114-119
    PubMedGoogle Scholar
  • 79 Wiser A, Kreiser D, Levron J, Dor J, Schiff E, Shulman A. Outcome of pregnancies complicated by moderate and severe OHSS: a follow up beyond the second trimester.  Fertil Steril. 2003;  80 178
    PubMedGoogle Scholar
  • 80 Van Nest R L, Stillman R J, Richter K S. Timing of presentation with severe OHSS predicts clinical IVF pregnancy.  Fertil Steril. 2003;  80 179
    PubMedGoogle Scholar
  • 81 Tozer A J, Iles R K, Iammarrone E, Gillott C MY, Al-Shawaf T, Grudzinskas J G. The effects of ‘coasting’ on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome.  Hum Reprod. 2004;  DOI: 10.1093/humrep/deh096.1-7
    PubMedGoogle Scholar

Dr. med. Helge Binder

Frauenklinik
Universitätsklinikum Erlangen

Universitätsstr. 21 - 23

91054 Erlangen

Email: helge.binder@gyn.imed.uni-erlangen.de